First patient has been enrolled in a Phase 1a/b study with Atrogi’s drug candidate ATR-258.

First patient has been enrolled in a Phase 1a/b study with Atrogi’s drug candidate ATR-258.

Our partner Atrogi announces first patient treated with its ATR-258 ß\2\ adrenoceptor agonist in a phase I clinical study for the treatment of type 2 diabetes – a milestone!

For more information, click here.

First patient has been enrolled in a Phase 1a/b study with Atrogi’s drug candidate ATR-258.

You May Also Like

New Whitepaper: New strategies to improve clinical outcomes for diabetic kidney disease